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Quality of life assessment using patient reported outcome (PRO) measures - 
still a Cinderella outcome? 
 
“….the person who takes medicine must recover twice, once from the disease, and 
once from the medicine” William Osler (1849-1919) 
 
William Osler was one of the first physicians to articulate the harms not just the 
benefits of modern medicine and a century since his pithy observation, we have 
seen many exciting advances made in the treatment of cancer. Better understanding 
of molecular biology together with improved diagnostics, surgical and radiotherapy 
techniques and innovative, more targeted systemic therapies mean that more 
patients have a genuine prospect of cure or surviving longer with their disease. 
Nothing comes without cost however and the iatrogenic harms and burdens, both 
acute and long-term, associated with novel drug therapies, remain under-reported, 
under-estimated and consequently under-treated.[1] To enable wise decision-making 
before embarking on different therapeutic management strategies, patients and 
doctors need much more information than that usually available in publications of 
many clinical treatment trials. How one functions and feels during and after treatment 
are salient concerns yet primary outcomes of studies are invariably overall survival 
(OS) and more commonly in advanced disease, progression free survival (PFS). The 
paper by Marandino et al. [2] shows an alarming dearth of quality of life (QoL) 
endpoints in major clinical trials of novel therapies in the common solid tumours. The 
authors illustrate how even when patient assessments were included in the trials, the 
results were generally insufficiently reported, subject to significant publication delays 
long after those of the main trial and were often found in low impact journals.  
We have to do better in our evaluation of expensive novel products. The sometimes 
modest OS or more often PFS gains that excite clinical scientists and pharma share-
holders, may be of little value to patients experiencing some serious and 
burdensome side-effects. Conclusions stating that ‘patients found side-effects 
tolerable’ should be viewed with some skepticism as trials that are conducted for 
registration and licensing purposes rarely have lengthy enough follow-up to chart 
some of the problems that emerge later in the clinic.[3] 
There are many other reasons to be concerned about the quality of the traditional 
adverse event (AE) data derived from clinical trials. There is a lack of concordance 
between toxicity and symptom recording by patients using PROs and the ‘gold- 
standard’ for establishing AEs namely the Common Terminology Criteria of Adverse 
Events (CTCAEs) graded by clinicians.[4]  Worryingly although AE grades are 
regarded as objective many even experienced clinicians are unaware of the precise 
definitions for the different grades. Furthermore studies show quite poor inter-rater 
reliability between clinicians asked to rate the same symptom. [5]  
Unfortunately there is little reason for complacency about some of the trial 
publications that do include QoL from patient reported outcome measures (PROMs). 
A myriad of deficiencies can be observed including: - inappropriate choice of PRO, 
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inadequate descriptions as to how missing data were handled and naïve or biased 
statistical methods to name but a few.  
Just because a questionnaire purports to measure quality of life, this does not 
necessarily mean that it is suitable for the patient population, their disease status or 
the treatments being trialed. Many commonly used generic PROMs such as the 
EORTC-QLQ-C30 [6] and the FACT-G [7], which are multi-dimensional with domains 
covering areas such as physical, functional, social, sexual and emotional well-being. 
Reporting merely the mean total scores from such measures can mask or dilute 
important effects, both positive and negative, that might exist at a domain level. Both 
the EORTC and FACT-G can be accompanied by disease specific modules or 
subscales that contain important relevant items. The FACIT system has a whole 
suite of subscales that are treatment specific permitting better evaluation of 
symptoms associated with, for example, monoclonal antibodies, TKIs, hormone 
therapies, taxanes and anti-angiogenisis drugs.[8]  
In oncology trials especially those conducted in tumour sites with a poor prognosis or 
in advanced disease, attrition is inevitable and a major challenge. If one treatment 
arm is significantly more effective than another, then missing data are unlikely to be 
missing at random and sophisticated statistical methods are required. At the very 
least it is vital that at an individual item, questionnaire or patient level, the reasons for 
missing data be that toxicity, progression or death, are available for scrutiny. 
CTCAE grades only offer information regarding the presence at any time of a 
symptom. Good PRO measures when analyzed appropriately, can provide a clearer 
description of the trajectory of important side effects, when they start, if they ever 
improve or if they persist until end of treatment. Group mean scores are not very 
helpful for individual decision-making, so responder analyses showing what 
proportion of patients, in each treatment arm, at each time point, ever improve from 
baseline, remain stable or decline are useful for decision-making. 
There are many suitable rigorously validated PRO measures to consider if we are 
serious about charting the multiple, putative harms and benefits of novel drugs. Both 
the FDA and the EMA have recognised the need and published guidance on 
measures they would consider for label claims. [9, 10]  
Trialists might also think about including the Patient-Reported Outcomes version of 
the Common Terminology Criteria for Adverse Events (PRO-CTCAE) developed by 
the US National Cancer Institute (NCI) initiative to introduce patient-reported 
outcomes as a standard component of adverse-event monitoring in NCI-sponsored 
trials. [11]  
Any endpoint in a clinical trial requires thought, and it is important to challenge the 
cynical viewpoint still held by some that QoL endpoints are something that has to be 
included but is not really that pertinent for pharmacovigilance or decision-making. 
The unscientific approach of adding in any vaguely relevant measure to the trial 
protocol as an afterthought must end. Finally if conducted well with employment of 
rigorous methodology, then proper respect should be given to the resultant patient 
reported data which deserve to be published fully along with the main study results. 
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